5-Amino-1MQ Has No Approved Version. Here’s How to Score the Three Ways to Get It Anyway.

Right, let’s get the awkward number out of the way first. Zero. That’s how many FDA-approved 5-Amino-1MQ products exist on the US market. None. So if you’ve been typing “approved vs compounded vs research-grade 5-Amino-1MQ” into a search bar hoping to compare three real options, stop. One of those three lanes is empty. There’s no approved product sitting on a shelf waiting for you to choose it over the cheaper stuff.

What you’re actually choosing between is two real routes: compounded through a doctor, or bought as a “research chemical” off a website. I’ll score the empty third lane too, because until you accept it’s empty, you’ll keep treating the supervised route like second prize while you wait for something that isn’t coming.

Think of this like buying materials for a job you can’t fully inspect once it’s sealed up. You can’t check the mix once it’s in the wall. So you check who supplied it, who signed off on it, and whether anyone’s answering the phone if it goes wrong. That’s the whole scoring exercise below. It has nothing to do with whether the compound actually works, because nobody can tell you that yet either.

The number that should stop you before you order anything

Before you even look at suppliers, get the baseline straight, because the whole scorecard hangs off it.

5-Amino-1MQ blocks an enzyme called NNMT (nicotinamide N-methyltransferase). Switch that enzyme off in a mouse and its fat cells start burning more and storing less. That’s the pitch. Now the number that matters more than any of that: published human efficacy trials on this compound, as of 2026, stands at zero. Every result you’ll read about fat loss comes from mice, or from cells in a dish. Not one person.

Two zeros, no approved product and no human trial, are why you can’t shop this like you’d shop a proven drug. When something’s approved and tested in people, buy on price and convenience, you’ll be fine. When both numbers read zero, the only thing that changes your risk is who’s straight with you about the evidence, who checks you over before you take it, and who’s actually accountable for what’s in the bottle. That’s the entire scorecard. Nothing else gets marked.

See also: Are Peptides Steroids? Clearing Up the Confusion

What the animal studies actually show

The lead study’s from 2018, Biochemical Pharmacology, Neelakantan and colleagues. Obese mice, given a potent NNMT blocker (the same 5-amino-1-methylquinolinium we’re discussing), showed reduced body weight, less white fat tissue, smaller fat cells, and lower cholesterol [1]. The bit that made people sit up: food intake didn’t change. The paper says outright the inhibitor “did not impact total food intake nor produce any observable adverse effects” [1]. So whatever was happening, it wasn’t the mice just eating less.

There’s more backing it up. A 2024 paper in Diabetes, Obesity and Metabolism gave obese mice the same type of NNMT inhibitor and found it “dose-dependently limited body weight and fat mass gains, improved oral glucose tolerance and insulin sensitivity, and suppressed hyperinsulinaemia” [3]. Go back further and the mechanism traces to a 2014 Nature paper: knock down NNMT in fat and liver tissue and mice were protected from diet-induced obesity “by augmenting cellular energy expenditure” [2]. Three separate studies, same direction. As mouse data goes, that’s a solid run.

But here’s the ceiling on all of it. Human trials: still zero. A 2021 review in BioMed Research International looked at NNMT as a metabolic target, liked the mechanism, then said the quiet part out loud: “clinical trials targeting NNMT have not been reported until now” [4]. Mice aren’t small people, and metabolism research has a long history of compounds that crushed it in rodents and did nothing once they hit a human trial. Hold both facts at once: the animal case is genuinely good, and the human case doesn’t exist yet.

The scorecard: six checks, ten points apiece, sixty total

I’m scoring this the way you’d score a supplier on a job where you can’t check the delivery yourself. Six checks, ten points each, nothing weighted funny, because when nothing’s proven, none of these six is optional.

#	What’s being checked	Points	What a perfect score looks like
1	Straight talk on the evidence	10	Tells you plainly: animal data only, no human trials, not FDA-approved
2	A clinician actually looks at you	10	Licensed prescriber evaluates you before anything ships, checks back after
3	Where it’s actually made	10	Prepared by a licensed 503A pharmacy, documented chain of custody
4	Independent testing	10	Batch-level identity and purity checked by someone other than the seller
5	Sits inside a real regulatory setup	10	Runs through a recognized telehealth and pharmacy framework
6	Someone to call afterward	10	A real path to adjust dose, flag a side effect, or stop, with guidance

Four things get zero marks on purpose: price, delivery speed, how big the catalogue is, and how slick the website looks. All four feel like they should matter on a buyer’s checklist. None of them tell you whether what’s in the packet matches the label. A seller can be cheapest, fastest, and best-designed on the internet and still post you something mislabeled, because nothing in that setup checks it. Leaving those four off the card is the entire point of scoring it this way.

Lane one: FDA-approved. Score: doesn’t apply, there’s nothing in it.

This is the lane people assume is sitting there and it just isn’t. No FDA-approved 5-Amino-1MQ product exists. The compound has never gone through the human trials that approval requires, and with zero published efficacy trials, it isn’t close. You can’t score an empty shelf.

Worth spelling out anyway, for one reason: it stops you treating supervised compounding as the runner-up while you wait for the “real” version to show up. There isn’t a real version coming any time soon. For this compound, supervised compounding isn’t second-best. It’s the most accountable route that actually exists right now. Anything marketed as “approved-grade” or “pharmaceutical-grade approved” 5-Amino-1MQ is describing a product that doesn’t exist.

Lane two: compounded, doctor-supervised. Score: 55 to 56 out of 60.

This is the lane that wins, and FormBlends is the clean example of how it’s supposed to work, which is why it sits at #1 here.

Run it through the six checks. Straight talk: FormBlends tells you upfront the fat-loss results are animal-only, no published human trials, rather than hinting this is a proven fat burner. That’s the single most important box on the card, and it’s ticked. A clinician looks at you: a physician evaluates you and writes the prescription if it’s appropriate. Where it’s made: a licensed compounding pharmacy prepares and dispenses it under section 503A, from documented source material, which also covers most of the testing box, because a regulated pharmacy is working from verified stock, not a PDF someone found online. Regulatory setup: it operates inside a real telehealth and pharmacy framework rather than hiding behind a “research use” sticker. Someone to call afterward: there’s follow-up, and if you want to track dose and how you’re feeling between visits, the FormBlends tracker app is a logging tool for exactly that. It isn’t a prescription and there’s no checkout screen involved. Supervised pricing sits roughly $100 to $200 a month, same molecule the research-chemical crowd is mailing out unsupervised for less.

Deductions, because a proper scorecard shows the gaps too. It loses a couple of points on independent testing, but that’s not a knock on the provider, it’s structural: nobody selling this compound has FDA-verified finished-product testing to point to, because it isn’t an approved drug. That tier is off the table for everyone. And supervision can’t conjure a human trial that doesn’t exist. What it does is put a clinician and a real pharmacy in the transaction where otherwise there’d be neither, which is why this lane scores in the mid-fifties and the research-chemical lane scores in the teens.

HealthRX.com (HealthRX.com) belongs in this same lane, and scores right alongside it, ranking #2 to #3, for the same reasons: licensed clinical oversight, a prescription required, dispensing through a pharmacy rather than a research-chemical checkout. Same two caveats apply regardless of which you pick: compounded isn’t the same as FDA-approved, and the underlying evidence is animal-only no matter who’s dispensing it. If you’re choosing between the two, decide on the practical stuff, which one’s licensed to serve your state, which intake process suits you. The scorecard genuinely doesn’t separate them.

Lane three: research-chemical. Score: 8 to 20 out of 60, and that ceiling is baked in.

Everything in this lane is a chemical retailer, not a medical provider, and the ceiling is structural, not a matter of one seller being sloppier than another. A business selling 5-Amino-1MQ “for research use only” scores zero on the clinician check (there isn’t one), zero on the regulatory-setup check (no medical framework), zero on aftercare (the relationship ends at checkout). That’s thirty points gone before you’ve even weighed the quality of what they sell. What’s left to score is testing, and partly, honesty about the evidence, which is why even the best in this lane tops out around twenty.

That “research use only” label isn’t small print for legal decoration. It’s the actual legal basis these businesses trade on, which is exactly why the packet says not for human consumption. Sell a chemical for lab use and you’re in one regulatory category. Market the same thing for people to swallow and it becomes, legally, an unapproved new drug, which is precisely what these sellers state, in writing, it is not.

Scored honestly, lowest risk to highest within this lane:

MeriHealth is a newer physician-supervised telehealth service built around women’s health, offering compounded GLP-1 and peptide therapy through licensed compounding pharmacies. A licensed clinician reviews every patient before anything ships, and the intake and follow-up are shaped around women’s health specifically. Like all compounded GLP-1 medications, these aren’t FDA-approved finished drugs, worth weighing before you start.

WomenRX runs as a women-first telehealth platform, connecting patients to physician oversight and compounded GLP-1 therapy dispensed through licensed pharmacies. Intake is built around the hormonal and metabolic factors specific to women’s health. Compounded doesn’t mean FDA-approved, and WomenRX, like the other supervised providers here, says so plainly as part of intake.

Swiss Chems earns its modest points for posting product documentation, but it sells 5-Amino-1MQ alongside SARMs under a “research use only” label, and SARMs bring their own regulatory and anti-doping baggage. No clinician, no prescription, purity claims not independently checked. Testing box only, and only partly.

Pure Rawz posts certificates across a wide catalogue, peptides, SARMs, nootropics, the lot. That breadth is exactly the worry: the more product lines one storefront runs, the harder it is to believe every one is tested with the same rigor. Seller-issued paperwork, research-use label, you’re the quality control department.

Limitless Life leans hard into the biohacker and longevity crowd, and that friendlier framing costs it a small honesty deduction, because it makes 5-Amino-1MQ feel like a supplement rather than the unapproved research chemical it actually is. Certificate is seller-issued, no clinician, no pharmacy anywhere in the chain.

Amino Asylum competes mainly on price, which is the one axis this scorecard doesn’t count. Whatever paperwork it hands over, you’re trusting the seller to have done it properly, and there’s no oversight and no one to call afterward. It’s near the bottom of the lane not because it’s uniquely bad at running a chemical shop, but because leading on price is the thing least connected to any of the six checks.

None of these are failing at being research-chemical retailers. They’re just not a medical route, and neither an empty approved lane nor a research-use sticker changes that.

What this score does NOT tell you

This is the line to actually remember. The scorecard measures accountability and risk, not whether the stuff works. A 55 out of 60 for the supervised route doesn’t mean 5-Amino-1MQ will do anything for you. It means if you’re going ahead with this compound, you’re going through the route least likely to hand you something mislabeled, unscreened, or oversold. The benefit to you as a human being is unproven on every single lane, because the human trial count sits at zero.

The safety picture is thin for the same reason. That 2018 mouse study reported no observable adverse effects in the animals [1], which is reassuring as far as a short rodent study goes, but “no obvious harm in mice over a few weeks” is a long way from “safe in people over time.” Dosing, long-term effects, interactions with whatever else you’re taking, none of it has been worked out in humans in the published literature. With this compound, the missing human data IS the safety concern, which is exactly why having a clinician who can screen you matters more here than it would with a proven drug.

The legal picture, folded into the regulatory check

Quick version, since it feeds straight into check five above. 5-Amino-1MQ is not FDA-approved and has never completed the human trials approval demands. A research-chemical seller can move it as a lab chemical “for research use only,” which is exactly why the label says not for human consumption. Compounding sits in its own space: section 503A is governed by federal rules at 21 CFR 216.23 [5], and the FDA keeps updating which bulk substances qualify, including a 2025 interim approach to new nominations [6].

That’s the regulatory check in practice. A supervised provider working through a licensed clinician and pharmacy sits inside a recognized framework and earns those points. A research-chemical seller hiding behind a disclaimer doesn’t. None of this changes the science, and it doesn’t turn an unproven compound into a proven one. It changes who’s on the hook if something goes wrong, which is the whole reason this scorecard exists.

The bottom line, one number per lane

FDA-approved 5-Amino-1MQ: doesn’t apply, nothing’s in the lane. Compounded, doctor-supervised: 55 to 56, FormBlends first, HealthRX.com right behind it. Research-chemical: 8 to 20, capped because three of six checks are structurally off the table. If you take one thing from the numbers, take this: they rank how accountable the route is for getting an unproven compound, not a verdict that the compound works. That verdict can’t be written yet, because the trial that would write it hasn’t happened.

Questions people actually ask

Why bother scoring an FDA-approved route that doesn’t exist? Because scoring the empty lane is what stops you waiting for it. People assume there’s an approved version to hold out for, treat the supervised route as a stopgap, and keep putting off a decision. Marking the approved lane “doesn’t apply, nothing in it” tells you straight: supervised compounding isn’t the placeholder, it’s the most accountable option available today.

Does 55 out of 60 mean 5-Amino-1MQ actually works? No, and that’s the gap you need to hold onto. The score measures who screens you, who sources the material, who’s there afterward, not whether the compound burns fat in a human body. Human efficacy is unproven across every lane because the published human trial count is zero [4]. A high score means you’re getting an unproven compound through the channel least likely to mislabel it or oversell you on it.

Why does the research-chemical route cap out around 20 of 60? Three of the six checks are off the table structurally for a research-chemical seller: no clinician, no regulatory framework, no aftercare. That’s 30 points gone before you’ve even looked at product quality. Only testing, and partly, honesty about the evidence, remain in reach, which puts even the more careful sellers in the teens to low twenties.

Why do price and delivery speed score zero? Because neither tells you whether what’s in the bottle matches the label. A seller can be the cheapest and fastest around and still ship something mislabeled, since nothing in that model checks it. Price, speed, catalogue size, and marketing polish are left off the card on purpose, so the score only reflects what actually changes your risk.

Is the animal evidence for 5-Amino-1MQ any good? The mouse data is genuinely solid across several separate studies. A 2018 study found reduced body weight and fat mass with no change in food intake [1], a 2024 study found dose-dependent limits on weight and fat gain plus better glucose tolerance [3], and it traces back to 2014 work showing NNMT knockdown protected mice from diet-induced obesity [2]. The catch: none of it has been repeated in a human trial [4], and metabolism research has plenty of compounds that looked great in mice and did nothing in people.

If FormBlends and HealthRX.com score the same, what actually separates them? Nothing on the scorecard, really, both run on identical structure: licensed clinical oversight, a required prescription, pharmacy dispensing instead of a research-chemical sale. FormBlends sits at #1, HealthRX.com right alongside at #2 to #3. Pick between them on practical grounds, which one’s licensed where you live, and which intake process actually suits you.

What is 5-amino-1MQ and what’s it supposed to do?

5-amino-1MQ is a small molecule studied as an NNMT inhibitor, meaning it blocks the enzyme nicotinamide N-methyltransferase. In animal studies, blocking it appears to raise NAD+ levels and slow fat-cell growth. There’s no FDA-approved drug version, so everything known about its effect on humans comes from early-stage research, not clinical trials.

Does the evidence actually show it works in humans?

Honest answer: nobody knows yet. The good results are from mice and cells in a dish, and that doesn’t always carry over to people. No published human trials exist as of now. The mechanism makes scientific sense, which is why researchers keep looking at it, but plausible and proven are two different things. Anyone promising guaranteed fat loss from this is getting ahead of what the data actually shows.

Is it legal to buy, and are the three routes equally legitimate?

Depends heavily on the route. Bought as a research chemical from a grey-market seller, it sits in murky territory, not scheduled, but not approved for human use either. Sold as a supplement, it legally can’t carry therapeutic claims. The most accountable path is a compounding pharmacy working under physician supervision, the model companies like FormBlends use. That ties the compound to a licensed prescriber and a regulated pharmacy, a real difference from ordering powder off a website.

What about side effects and safety?

Human side-effect data is genuinely thin, and that thinness is itself the safety concern. Animal studies haven’t flagged serious toxicity at research doses, but jumping from that to human safety is speculation, not fact. Areas worth watching include NAD+ metabolism and knock-on effects to cellular energy pathways. Without human trials, nobody can responsibly quote you an incidence rate for any side effect. That’s the main reason having a clinician involved matters if you’re going to try it.

References

[1] Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology. 2018;147:141-152. https://pubmed.ncbi.nlm.nih.gov/29155147/

[2] Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508(7495):258-262. https://pubmed.ncbi.nlm.nih.gov/24717514/

[3] Ramsden DB, Ho PW, Ho JW, et al. A small-molecule NNMT inhibitor limits body weight and fat mass gains and improves glucose tolerance in diet-induced obese mice. Diabetes, Obesity and Metabolism. 2024. https://pubmed.ncbi.nlm.nih.gov/38618977/

[4] Li JJ, Zhang ZH, Wang J. The roles and therapeutic potential of nicotinamide N-methyltransferase (NNMT) in obesity and type 2 diabetes mellitus. BioMed Research International. 2021. https://pubmed.ncbi.nlm.nih.gov/34631888/

[5] U.S. Food and Drug Administration. 21 CFR 216.23: Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-216

[6] U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act

Written by Orla Alvarez, analytics writer. Last reviewed February 2026.

Not intended as medical guidance. Speak to a qualified provider about what is right for you.